South Delhi Pharma, New Delhi, India

KEYTRUDA (pembrolizumab) injection, for intravenous use

SDP are here to serve you through the quality pharmaceutical products as per your needs. Established in the year 1996, we have earned a global reputation in the market. Owing to superior quality widest range of Anti Cancer medicines.

Facts of Keytruda (pembrolizumab)

KEYTRUDA® (pembrolizumab) injection, for intravenous use
Initial U.S. Approval: 2014
Generic Name: pembrolizumab
Company: Merck & Co
Mechanism of Action: Programmed cell death protein 1 (PD1) antibody

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Keytruda (pembrolizumab) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Keytruda (pembrolizumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

10 + 6 =

What Keytruda is?

KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:

Skin cancer called melanoma, Lung cancer called non–small cell lung cancer (NSCLC), Head and neck squamous cell cancer (HNSCC), classical Hodgkin lymphoma (cHL). Bladder and urinary tract cancer called urothelial carcinoma, Laboratory test to be a microsatellite instability-high (MSI-H) or a mismatch repair deficient (dMMR) solid tumor, Stomach cancer called gastric or gastroesophageal junction (GEJ), squamous cell carcinoma of the esophagus, Cervical cancer, Liver cancer, Skin cancer, Kidney cancer.

What pembrolizumab is?

Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.

As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who can't receive cisplatin-based chemotherapy and have high levels of PD-L1, as a second-line treatment for head and neck squamous cell carcinoma (HNSCC), after platinum-based chemotherapy, for the treatment of adult and pediatric patients with refractory classic Hodgkin's lymphoma (cHL), and recurrent locally advanced or metastatic esophageal squamous cell carcinoma.

In 2017, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for any unresectable or metastatic solid tumor with certain genetic anomalies (mismatch repair deficiency or microsatellite instability). This was the first time the FDA approved a cancer drug based on tumor genetics rather than tissue type or tumor site;[medical citation needed] therefore, pembrolizumab is a so-called tissue-agnostic drug.

Reviews

There are no reviews yet.

Be the first to review “KEYTRUDA (pembrolizumab) injection, for intravenous use”

Your email address will not be published. Required fields are marked *